重组人血小板源性生长因子凝胶剂促进糖尿病大鼠创面愈合的实验研究

目的 :研究重组人血小板源性生长因子 (rh PDGF BB)凝胶剂对糖尿病大鼠皮肤切割伤创面修复的作用及其量效关系。方法 :13只糖尿病大鼠在背部各制备 4个全层皮肤缺损创面 ,面积 2 .5 4 cm2 ,将创面分成5组 ,即 rh PDGF BB凝胶剂高剂量 (14 .0μg/ cm2 创面 )、中剂量 (7.0μg/ cm2 创面 )、低剂量 (3.5μg/ cm2 创面 ) 3组 ,凝胶剂基质对照组以及空白对照组。创面局部应用制剂 14 d,观察伤后不同时间各组创面面积、伤腔容积变化及组织学改变。结果 :伤后 14 d rh PDGF BB高、中、低剂量治疗组创面面积分别缩小至 (0 .2 2±0 .30 ) cm2、(0 .0 5± 0 .0 6 ) cm2和 (0 .32± 0 .32 ) cm2 ,中剂量组明显小于凝胶剂基质对照组 (0 .2 3± 0 .2 2 ) cm2 (P<0 .0 5 )和空白对照组 (0 .2 2± 0 .2 5 ) cm2 (P<0 .0 5 )。伤后 7d rh PDGF BB高、中、低剂量治疗组伤腔容积减小至(0 .0 4± 0 .0 3) m l、(0 .0 2± 0 .0 2 ) ml和 (0 .0 6± 0 .0 3) ml,只有中剂量组明显小于凝胶剂基质对照组 (0 .0 6±0 .0 3) m l(P<0 .0 5 )和空白对照组 (0 .0 7± 0 .0 5 ) m l(P<0 .0 5 )。组织学检查显示 ,经 rh PDGF BB中剂量治疗的创面伤后 7d肉芽组织生长活跃 ,其毛细血管胚芽与成纤维细胞数量显著多于其他组 ,伤后 14 d rh

Experimental study on recombinant human platelet-derived growth factor gel in a diabetic rat model of cutaneous incisal wound healing

OBJECTIVE: To investigate the effect of recombinant human platelet-derived growth factor (rhPDGF-BB) on cutaneous incisal wound healing in diabetic rats and this factor does-effect relationship. METHODS: Thirty Wistar diabetic rats were used in this study. Four full-thickness skin wounds of 2.54 cm(2) were incised in the back of each rat. The wounds were divided into five groups: three groups were treated with different dosage of rhPDGF-BB gel (14.0 microg/cm(2) wound, 7.0 microg/cm(2) wound, 3.5 microg/cm(2) wound), other two groups were treated with vehicle or untreated, respectively. rhPDGF-BB gel was topically applied to the wounds from 1 to 14 days. The wound healing effect was assessed by the measurements of the wound area, subcutaneous chamber and histological changes of each group. RESULTS: On 14 days, the wounds of the three groups treated with rhPDGF-BB contracted to (0.22+/-0.30)cm(2), (0.05+/-0.06)cm(2), (0.32+/-0.32)cm(2), respectively. The area of the middle dosage groups was significantly smaller than those treated with vehicle 0.23+/-0.22 cm(2) (P<0.05) and untreated (0.22+/-0.25) cm(2) (P<0.05). On 7 days, the subcutaneous chambers of the three treated groups contracted to (0.04+/-0.03)ml, (0.02+/-0.02)ml, (0.06+/-0.03)ml, and there was a statistic significance when comparing middle dosage group with vehicle group (0.06+/-0.03) ml (P<0.05) and untreated group (0.07+/-0.05 ml (P<0.05). As for histological examination, much more granulation formation was shown in the wound bed in middle dosage group than that in other four groups on 7 days, and some of the wounds treated with middle dosage were healing on 14 days. CONCLUSION: It suggested that topical application of rhPDGF-BB might improve wound healing in diabetic rats. The effective dosage of rhPDGF-BB is 7.0 microg/cm(2) wound.